老年患者米安色林消除的变异性。
Variability in the elimination of mianserin in elderly patients.
作者信息
Begg E J, Sharman J R, Kidd J E, Sainsbury R, Clark D W
机构信息
Department of Clinical Pharmacology, Christchurch Hospital, New Zealand.
出版信息
Br J Clin Pharmacol. 1989 Apr;27(4):445-51. doi: 10.1111/j.1365-2125.1989.tb05392.x.
Abstract
- Two studies of the elimination of mianserin are reported. 2. In the first study, the oral clearance of mianserin was measured in 15 elderly patients at steady state. In a sub-group of eight patients who completed studies at two different doses there was evidence of enhanced oral clearance at the higher dose. 3. In the second study, the elimination half-life was estimated in 12 patients who were observed to have disproportionately high mianserin concentrations with respect to dose. All had half-lives greater than or equal to 2.5 days with a mean of 6 +/- 2.8 (s.d.) days. In six of the patients the profile of elimination was suggestive of saturable elimination. 4. The sparteine oxidation status was measured in seven of the patients showing slow mianserin elimination. Only one was a 'poor oxidiser' of sparteine, suggesting no concordance with this phenotype. 5. It is concluded that there is marked variability in the elimination of mianserin in elderly patients.
摘要
- 报告了两项关于米安色林消除情况的研究。2. 在第一项研究中，对15名老年患者在稳态时的米安色林口服清除率进行了测量。在以两种不同剂量完成研究的8名患者亚组中，有证据表明较高剂量时口服清除率有所提高。3. 在第二项研究中，对12名观察到米安色林浓度相对于剂量过高的患者的消除半衰期进行了估计。所有患者的半衰期均大于或等于2.5天，平均为6±2.8（标准差）天。其中6名患者的消除曲线提示存在饱和消除。4. 对7名米安色林消除缓慢的患者测量了司巴丁氧化状态。只有1名是司巴丁的“弱氧化者”，表明与该表型不一致。5. 得出的结论是，老年患者中米安色林的消除存在显著差异。
相似文献
1
Variability in the elimination of mianserin in elderly patients.老年患者米安色林消除的变异性。
Br J Clin Pharmacol. 1989 Apr;27(4):445-51. doi: 10.1111/j.1365-2125.1989.tb05392.x.
2
The pharmacokinetics of mianserin.米安色林的药代动力学。
Br J Clin Pharmacol. 1983;15 Suppl 2(Suppl 2):313S-322S. doi: 10.1111/j.1365-2125.1983.tb05880.x.
3
Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: nonlinearity and relation to the sparteine oxidation polymorphism.
Clin Pharmacol Ther. 1992 Mar;51(3):288-95. doi: 10.1038/clpt.1992.24.
4
Factors affecting the kinetics of two benzothiazine non-steroidal anti-inflammatory medicines, piroxicam and isoxicam.影响两种苯并噻嗪类非甾体抗炎药（吡罗昔康和异恶酰胺）动力学的因素。
Eur J Clin Pharmacol. 1985;28(6):689-92. doi: 10.1007/BF00607917.
5
The relationship between paroxetine and the sparteine oxidation polymorphism.
Clin Pharmacol Ther. 1992 Mar;51(3):278-87. doi: 10.1038/clpt.1992.23.
6
Plasma concentrations of mianserin after single dose and at steady-state in depressed elderly patients.老年抑郁症患者单次给药后及稳态时米安色林的血药浓度。
Clin Pharmacokinet. 1987 Jan;12(1):73-8. doi: 10.2165/00003088-198712010-00005.
7
Quinidine kinetics after a single oral dose in relation to the sparteine oxidation polymorphism in man.单次口服奎尼丁后人体动力学与司巴丁氧化多态性的关系。
Br J Clin Pharmacol. 1990 Feb;29(2):248-53. doi: 10.1111/j.1365-2125.1990.tb03628.x.
8
Serum levels of mianserin and clinical outcome in elderly depressive inpatients.老年住院抑郁症患者的米安色林血清水平与临床结局
Isr J Psychiatry Relat Sci. 1992;28(4):64-8.
9
The influence of enzyme induction on polymorphic sparteine oxidation.酶诱导对多态性司巴丁氧化的影响。
Br J Clin Pharmacol. 1986 Jul;22(1):49-53. doi: 10.1111/j.1365-2125.1986.tb02879.x.
10
Influence of the defective metabolism of sparteine on its pharmacokinetics.
Eur J Clin Pharmacol. 1979 Sep;16(3):189-94. doi: 10.1007/BF00562060.
引用本文的文献
1
Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.人细胞色素 P450 2D6 的多态性及其临床意义：第二部分。
Clin Pharmacokinet. 2009;48(12):761-804. doi: 10.2165/11318070-000000000-00000.
2
Antidepressants in the elderly: challenges for study design and their interpretation.老年人使用抗抑郁药：研究设计及其解读面临的挑战
Br J Clin Pharmacol. 2000 Jun;49(6):539-47. doi: 10.1046/j.1365-2125.2000.00201.x.
3
Choosing appropriate antidepressant therapy in the elderly. A risk-benefit assessment of available agents.为老年人选择合适的抗抑郁治疗。对现有药物的风险效益评估。
Drugs Aging. 1998 Oct;13(4):269-80. doi: 10.2165/00002512-199813040-00003.
4
Pharmacokinetic optimisation of therapy with newer antidepressants.新型抗抑郁药治疗的药代动力学优化
Clin Pharmacokinet. 1994 Oct;27(4):307-30. doi: 10.2165/00003088-199427040-00005.
5
Adverse effects of antidepressants in the elderly.
Drugs Aging. 1992 Sep-Oct;2(5):450-8. doi: 10.2165/00002512-199202050-00008.
本文引用的文献
1
Polymorphic oxidation of sparteine and debrisoquine: related pharmacogenetic entities.鹰爪豆碱和异喹胍的多态性氧化：相关药物遗传学实体。
Clin Pharmacol Ther. 1982 Feb;31(2):184-6. doi: 10.1038/clpt.1982.29.
2
Plasma levels of the antidepressant drug mianserin: relevance to clinical pharmacology and therapy.抗抑郁药米安色林的血浆水平：与临床药理学及治疗的相关性。
Ther Drug Monit. 1980;2(1):95. doi: 10.1097/00007691-198001000-00011.
3
Mianserin kinetics in depressed patients.米安色林在抑郁症患者中的药代动力学。
Clin Pharmacol Ther. 1983 Jun;33(6):757-62. doi: 10.1038/clpt.1983.103.
4
The pharmacokinetics of mianserin.米安色林的药代动力学。
Br J Clin Pharmacol. 1983;15 Suppl 2(Suppl 2):313S-322S. doi: 10.1111/j.1365-2125.1983.tb05880.x.
5
Mianserin and blood dyscrasias.米安色林与血液系统疾病。
Br J Clin Pharmacol. 1983;15 Suppl 2(Suppl 2):291S-293S. doi: 10.1111/j.1365-2125.1983.tb05877.x.
6
The potential therapeutic role of the enantiomers and metabolites of mianserin.米安色林对映体及代谢产物的潜在治疗作用。
Br J Clin Pharmacol. 1983;15 Suppl 2(Suppl 2):269S-276S. doi: 10.1111/j.1365-2125.1983.tb05875.x.
7
Influence of age on mianserin pharmacokinetics.年龄对米安色林药代动力学的影响。
Psychopharmacology (Berl). 1982;78(4):380-2. doi: 10.1007/BF00433747.
8
The pharmacokinetics of mianserin in elderly depressed patients.米安色林在老年抑郁症患者中的药代动力学。
Psychiatry Res. 1983 Apr;8(4):281-7. doi: 10.1016/0165-1781(83)90016-1.
9
Amitriptyline metabolism: association with debrisoquin hydroxylation in nonsmokers.阿米替林代谢：与非吸烟者中异喹胍羟化作用的关联。
Clin Pharmacol Ther. 1986 Apr;39(4):369-71. doi: 10.1038/clpt.1986.56.
10
Possible mechanism for mianserin induced neutropenia associated with saturable elimination kinetics.米安色林诱导中性粒细胞减少症与可饱和消除动力学相关的可能机制。
Br Med J (Clin Res Ed). 1985 Nov 16;291(6506):1375-6. doi: 10.1136/bmj.291.6506.1375.
Zotero 插件